Education center

Metabolic protocols, the way the books frame them.

ISSCA's metabolic chapter is about labeled GLP-1 medicines, semaglutide, tirzepatide, liraglutide, used under a prescriber and according to the label, not a research "fat peptide" from a chat. Protein and lifting are mandatory so you do not melt muscle. Mr. Pep shows what the compounds are and how they are sequenced. It does not hand you a personal dose to inject. A clinician decides that.

core

CJC-1295 + Ipamorelin

Nighttime GH-pulse support for recovery and lean mass. Needs a working pituitary.

GHRH analogue + GH secretagogue (ghrelin-receptor agonist)

Sermorelin was previously an FDA-approved GHRH analogue (later discontinued as a brand). Tesamorelin is FDA-approved for HIV-associated lipodystrophy. CJC-1295 and ipamorelin used in clinics are typically compounded / research peptides, not approved GH-replacement drugs.

Dual-pathway stimulation of physiologic GH pulses: a GHRH analogue (CJC-1295 no-DAC / Mod GRF 1-29 or sermorelin) plus a ghrelin-receptor agonist (ipamorelin preferred in ISSCA for selectivity). Requires a working pituitary. Benefits accrue over 8 to 12 weeks. Night / empty-stomach timing is emphasized.

Common-practice ranges, not a personal dose

Quick-reference combo (Vol 1 Ch.1)

CJC-1295 + Ipamorelin 200 mcg + 300 mcg nightly.

VOL1 · Chapter 1 · p.12

CJC-1295 without DAC (Vol 1 Ch.8)

100 to 300 μg per injection, 2 to 3 times weekly, before bed or 2 to 3 hours post-meal. Preferred for pulsatile pattern.

VOL1 · Chapter 8 · p.99

CJC-1295 with DAC (Vol 1 Ch.8)

1 to 2 mg once weekly. More convenient, less physiologic, faster desensitization risk. Vol 1 Ch.9 lists 2 to 3 mg weekly.

VOL1 · Chapters 8 to 9 · p.100, 113

Ipamorelin (Vol 1 Ch.8)

200 to 300 μg once daily before bed, 30 to 60 minutes before sleep. Selective, fewer side effects.

VOL1 · Chapter 8 · p.100

Gold-standard combination (Vol 1 Ch.8)

CJC-1295 no-DAC 100 to 200 μg + ipamorelin 200 to 300 μg together before bed, 5 days/week. Cycle 12 weeks on / 4 weeks off.

VOL1 · Chapter 8 · p.101

Sermorelin (Vol 1 Ch.9)

200 to 500 μg SC before bed, 5 to 6 nights weekly, empty stomach, 3 to 6 month cycles.

VOL1 · Chapter 9 · p.112

Mod GRF 1-29 (Vol 1 Ch.9)

100 to 300 μg, 1 to 3 times daily on empty stomach (pre-meal, post-workout, or bedtime).

VOL1 · Chapter 9 · p.113

Hexarelin (advanced only)

Vol 1: 100 to 200 μg 1 to 2x daily with mandatory cycling. Vol 2: 100 to 200 μg once daily max, pre-sleep only, ≤4 week cycles. Highest desensitization risk.

VOL1+VOL2 · Vol 1 Ch.8; Vol 2 Ch.8 · p.100; 59 to 60

Tesamorelin (labeled / arsenal)

2 mg nightly in the Vol 1 quick-reference for visceral fat / metabolic enhancement. This is the FDA-labeled analogue family for HIV lipodystrophy, prescribe only to label.

VOL1 · Chapter 1 · p.12

Vol 2 preferred clinic pattern

CJC-1295 no-DAC 100 to 200 mcg SC 1 to 2x daily, pre-sleep mandatory. Ipamorelin 100 to 300 mcg SC 1 to 3x daily, pre-sleep ± post-training. Standard restoration protocol: CJC 100 mcg + ipamorelin 200 mcg pre-sleep for 8 to 12 weeks.

VOL2 · Chapter 8 · p.59 to 60

Cycle / washout. Vol 1 gold standard 12 on / 4 off. Vol 2 standard 8 to 12 weeks, washout 4 to 6 weeks. Hexarelin ≤4 weeks. Continuous use without breaks → receptor fatigue.

  • Active cancer (IGF-1 / tumor-growth theory)
  • Severe poorly controlled diabetes
  • Pregnancy / lactation
  • Pituitary failure (secretagogues cannot replace an absent axis)
  • Patients wanting overnight 'HGH bodybuilding' results
Flagged in the books: Active malignancy · Uncontrolled diabetes · Pregnancy / lactation · Non-functional pituitary · Daytime GH stacking that interferes with insulin during aggressive fat-loss phases (Vol 2)

Sources: Vol 1 Ch.1 p.12 · Vol 1 Ch.8 to 9 pp.96 to 119 · Vol 2 Ch.8 pp.59 to 60

approved

GLP-1 family (semaglutide, tirzepatide, liraglutide)

Labeled medicines for diabetes and weight, prescription, not a research fat vial.

Incretin / dual GIP-GLP-1 receptor agonists, prescription metabolic drugs

FDA-approved prescription medicines for type 2 diabetes and/or chronic weight management when labeled criteria are met. This is not a research peptide class. Compounded copies raise quality and legal issues; branded products have a boxed warning for thyroid C-cell tumors in rodents.

Medicines that mimic GLP-1 (tirzepatide also agonizes GIP). Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central appetite reduction. ISSCA also discusses longevity / NAFLD / CV-risk framing, but labeled indications and REMS/label warnings still govern real-world prescribing.

Common-practice ranges, not a personal dose

Quick-reference (Vol 1 Ch.1)

Semaglutide 0.25 to 2.4 mg weekly. Tirzepatide 2.5 to 15 mg weekly.

VOL1 · Chapter 1 · p.13

Liraglutide (Vol 1 Ch.10)

Start 0.6 mg SC daily, increase 0.6 mg weekly as tolerated, maintenance 1.2 to 3.0 mg daily (higher end for weight). Same time each day. Book notes 1.8 mg daily in a CV-protection protocol example.

VOL1 · Chapter 10 · p.123, 126

Semaglutide injectable (Vol 1 Ch.10)

Start 0.25 mg SC weekly. Titrate every 4 weeks: 0.25 → 0.5 → 1.0 → 2.4 mg. Maintenance 0.5 to 2.4 mg depending on indication. Same day each week.

VOL1 · Chapter 10 · p.124

Oral semaglutide (Vol 1 Ch.10)

Start 3 mg daily empty stomach; monthly 3 → 7 → 14 mg. First thing in the morning, wait 30+ minutes before food.

VOL1 · Chapter 10 · p.124

Tirzepatide (Vol 1 Ch.10)

Start 2.5 mg SC weekly. Increase 2.5 mg every 4 weeks as tolerated. Maintenance 5 to 15 mg. Max 15 mg for weight management.

VOL1 · Chapter 10 · p.124

Vol 2 metabolic protocol classes (conservative clinic style)

Many Vol 2 cards use 'GLP-1 peptide 0.25 to 0.5 mg weekly' as a low-and-slow educational pattern, escalate to 0.5 mg only if appetite suppression plateaus, 12-week minimum. Aggressive short-term class: 0.5 to 1.0 mg weekly for 8 to 10 weeks max then mandatory washout. These are protocol-class examples, not a substitute for the FDA titration schedule on the pen you were prescribed.

VOL2 · Chapter 17 · p.135

Cycle / washout. Approved indications are often long-term. ISSCA still talks about reassessment, lean-mass protection, and not starving. Vol 2 aggressive class is explicitly time-limited with washout because rebound follows failure to consolidate.

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • MEN2
  • Pregnancy or pregnancy planned within ~2 months (book language)
  • Severe gastroparesis
  • History of pancreatitis without a careful risk-benefit review
  • Cosmetic crash dieting without protein and resistance training
Flagged in the books: MTC personal or family history · MEN2 · Pregnancy · Severe gastroparesis · Pancreatitis history, specialist decision

Sources: Vol 1 Ch.10 pp.120 to 131 · Vol 1 Ch.1 p.13 · Vol 2 Ch.17

approved

Tesamorelin (visceral fat / GHRH analogue)

Labeled GHRH analogue for visceral fat in a specific population, prescription.

FDA-labeled GHRH analogue, metabolic / VAT

Tesamorelin is FDA-approved for HIV-associated lipodystrophy (visceral adipose reduction). ISSCA lists 2 mg nightly in the Volume 1 arsenal for visceral fat / metabolic enhancement. Labeled use is a prescription, not a research vial.

A stabilized GHRH analogue. Distinct from CJC-1295/ipamorelin compounding. The labeled indication is reduction of excess abdominal fat in HIV lipodystrophy. Off-label metabolic use is clinician territory.

Common-practice ranges, not a personal dose

ISSCA arsenal (Vol 1 Ch.1)

2 mg nightly for visceral fat reduction and metabolic enhancement, arsenal line. Follow the labeled product when a branded pen exists.

VOL1 · Chapter 1 · p.12

Cycle / washout. Labeled courses are prescriber-directed. Secretagogue cycling rules in Ch.8 to 9 do not automatically map onto branded tesamorelin.

  • Active malignancy (IGF-1 theory, same GH-axis caution)
  • Pregnancy
  • Uncontrolled diabetes without a prescriber
Flagged in the books: Active malignancy · Pregnancy · Pituitary context per label

Sources: Vol 1 Ch.1 p.12

What the first weeks tend to look like

A general, educational pattern, not a schedule to self-administer. Your prescriber sets dose, timing, and monitoring.

💊

0-24 hours

A labeled GLP-1 begins acting on appetite and blood-sugar signaling. Some people notice less hunger; many notice nothing on day one. Response is individual.

📉

First few days

Appetite suppression is often most noticeable. Nausea or fullness can appear as the body adjusts. A prescriber manages side effects and decides whether to hold or change anything.

🔥

Weeks 1-2

The body settles on the starting dose before any titration a clinician may choose. Protein and resistance training start now, not later, so you do not lose muscle with the fat.

⚡

Weeks 3-6

Early shifts in weight and blood-sugar patterns may appear. Volume 2 treats this as a slow, monitored process, not a crash. Dose changes stay with the prescriber and the label.

🧠

Long term

The Volume 2 objective is metabolic clarity, not the fastest possible weight loss. Muscle, sleep, and labs matter as much as the scale. A clinician owns the plan.

Browse every compound

The full library, not just the metabolic set. Pick a compound to open its ranges, cycling, and cautions. This is reference reading, not a shopping list or a prescription.

core

BPC-157

Repair peptide for stalled tendons, gut lining, and slow healing, not a painkiller.

Tissue repair / gastric-derived pentadecapeptide

Research / compounded in most jurisdictions. Not FDA-approved as a finished drug for injury or gut indications.

15-amino-acid fragment from human gastric juice (Body Protection Compound). Acid-stable enough that oral use is discussed for gut applications. Short plasma half-life (<30 minutes) with longer tissue signaling (VEGF / angiogenesis, growth-factor and nitric-oxide pathways, cell migration).

Common-practice ranges, not a personal dose

Quick-reference (Vol 1 Ch.1 arsenal)

250 to 500 mcg twice daily for gut, tendon, ligament, and muscle repair.

VOL1 · Chapter 1 · p.12

Systemic SC / IM (Vol 1 Ch.4)

Standard 200 to 500 µg daily, split into 1 to 2 injections. Duration 2 to 4 weeks acute, 6 to 8 weeks chronic. Rotate abdomen and thighs. Start 200 to 250 µg.

VOL1 · Chapter 4 · p.45 to 46

Localized peri-lesional (Vol 1 Ch.4)

100 to 200 µg per injection, 2 to 3 times weekly, 4 to 6 weeks, into or around target tissue.

VOL1 · Chapter 4 · p.45

Oral GI focus (Vol 1 Ch.4)

500 µg to 2 mg daily on an empty stomach, 4 to 8 weeks, capsule or oral solution (higher because of partial absorption).

VOL1 · Chapter 4 · p.46

Practical daily range used in Vol 2 protocols

250 to 500 mcg/day SC once daily or divided BID. Localized injury 250 to 500 mcg/day near (not into) tissue. GI: 250 to 500 mcg/day oral or SC. Clinical note: going above 500 to 750 mcg/day rarely helps and may rebound inflammation.

VOL2 · Chapter 4 · p.25 to 26

Cycle / washout. Vol 2: typical 4 to 6 weeks, up to 8 weeks chronic, washout 2 to 4 weeks. Re-cycle only if structural recovery is incomplete. If plateaued, do not escalate dose, reassess rehab, inflammation, or stacking.

  • First-line painkiller instead of rehab
  • Cosmetic or vague wellness without a repair target
  • Active malignancy (theoretical angiogenesis concern)
  • Pregnancy / lactation (no safety data)
Flagged in the books: Active malignancy (angiogenesis theory) · Pregnancy / lactation · Acute untreated severe infection · Using as a substitute for rest, loading, or surgery when those are required

Sources: Vol 1 Ch.1 pp.12 to 13 · Vol 1 Ch.4 pp.43 to 55 · Vol 2 Ch.4 pp.21 to 28

Educational only, not a prescription and not personal medical advice. Approved GLP-1 medicines must be used only under a licensed prescriber, according to the product label. Research or compounded peptides are not approved drugs. A clinician decides what you actually use.